Company Profile
Spruce Biosciences Stock Price, News & Catalysts
- Ticker:
- SPRB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
44.77 USD (-7.84%)
Close
Last updated: October 1, 2026
136M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, SPRB closed down 7.84% at $44.77. No new same-company headline was identified in the current news window.
Company overview
Rare Neurological Disease Company
Spruce Biosciences is developing therapies for serious neurological disorders with high unmet need. Its current strategy is centered on a potential disease-modifying treatment for Sanfilippo syndrome type B.
Tralesinidase Alfa Enzyme Replacement Therapy
Tralesinidase alfa is a recombinant NAGLU enzyme replacement therapy delivered into the cerebrospinal fluid. It is designed to clear accumulated heparan sulfate from the central nervous system in children with MPS IIIB.
Long-Term Clinical Evidence
The clinical package includes years of treatment experience showing sustained biomarker normalization and preservation of cognitive, communication, and motor outcomes relative to natural-history patients. The FDA has recognized the cerebrospinal-fluid biomarker as reasonably likely to predict clinical benefit.
Accelerated-Approval Strategy
Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations support an expedited regulatory pathway. Spruce is preparing a BLA based on the integrated clinical dataset and plans a confirmatory study to support full approval.
Commercial Readiness for a Rare Disease Launch
The company is building medical, market-access, and commercial capabilities for a concentrated pediatric rare-disease population. An expanded-access program is intended to make treatment available to additional eligible patients before a potential approval.
Confirmatory Evidence Plan
Spruce plans a post-approval confirmatory study to verify clinical benefit while continuing collection of long-term natural-history and treated-patient data. This work is central to converting a potential accelerated approval into full approval.
Future catalysts
- Submission of the BLA for tralesinidase alfa in the fourth quarter of 2026.
- Initiation of the tralesinidase alfa expanded-access program in the fourth quarter of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Spruce Biosciences (SPRB)?
Spruce Biosciences (SPRB) most recently closed at 44.77 USD, a -7.84% move versus the previous session.
What is the market cap of Spruce Biosciences (SPRB)?
Spruce Biosciences currently has a market capitalization of 136M USD on BioPharmSignal.
What does Spruce Biosciences do?
Rare Neurological Disease Company Spruce Biosciences is developing therapies for serious neurological disorders with high unmet need. Its current strategy is centered on a potential disease-modifying treatment for Sanfilippo syndrome type B. Tralesinidase Alfa Enzyme Replacement Therapy Tralesinidase alfa is a recombinant NAGLU enzyme replacement therapy...
On which exchange is SPRB stock listed?
Spruce Biosciences (SPRB) is associated with NASDAQ, United States, Biopharma.
What is Rare?
Rare Neurological Disease Company Spruce Biosciences is developing therapies for serious neurological disorders with high unmet need.
Which conditions is Spruce Biosciences targeting with Rare?
Spruce Biosciences is associated with rare disease based on its company overview and current catalyst commentary.
How does Spruce Biosciences describe recent progress with Rare?
Submission of the BLA for tralesinidase alfa in the fourth quarter of 2026. Initiation of the tralesinidase alfa expanded-access program in the fourth quarter of 2026.
What is Neurological?
Rare Neurological Disease Company Spruce Biosciences is developing therapies for serious neurological disorders with high unmet need.